Amersham Biosciences and geneticXchange Collaborate to Provide a New Platform for Life Science Data Management and Data Integration
July 10, 2003 – Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM), and geneticXchange, a leading provider of data access and integration solutions for the life sciences industry, have collaborated to provide the most powerful laboratory data acquisition, management and integration solution available on the market today.
The two companies have worked together to seamlessly combine Amersham Biosciences’ Scierra™ Laboratory Workflow System (LWS) and discoveryHub™ data integration platform from geneticXchange to provide scientists with increased transparency and accessibility to any laboratory-generated data. Available from Q3 2003, the powerful combination of Scierra LWS and discoveryHub will enable the rapid integration of laboratory-generated data with legacy, public, third party and clinical data on one platform that will help lead to tangible time and cost savings for drug discovery. Under a distribution agreement signed this week, Amersham Biosciences will sell the integrated solution globally. Financial terms were not disclosed.
By facilitating the flow of data that is generated from instruments and then making it available for further analysis, this collaboration underpins Amersham’s Data Fluency Informatics initiative – the drive for seamless integration of traditionally distinct disciplines of biology, technologies and scientific teams through data.
“The combination of Scierra LWS and discoveryHub offers a unique and powerful solution for data acquisition, data management and data integration for scientists,” says Jerry Walker, VP Informatics, at Amersham Biosciences. “Customers already benefit from the Scierra LWS technology that facilitates the generation, acquisition and management of data. The addition of discoveryHub will enable rapid integration of lab generated data with legacy, public, third party and clinical data, leading to both time and cost savings in the drug discovery process.”
” Amersham Biosciences’ vision of seamless data integration and management absolutely aligns with the geneticXchange plan to build a world-class data integration platform that will allow any life science organization to connect scientists to the data they need. This open platform combining Scierra LWS and discoveryHub underpins a major new data integration system for the industry,” said Brian Donnelly, CEO and Chairman of geneticXchange.
Amersham Biosciences Scierra LWS is a unified platform to support and manage data across multiple instruments, users, and applications. It is a family of flexible and efficient workflow-based software products and services for managing DNA and protein information gathered from discovery processes. The Scierra LWS can comprehensively track and manage samples from the point of sample acquisition through data analysis, and can be customized to meet the specific needs of each client’s laboratory data collection and analysis environment.
The geneticXchange discoveryHub is a fast, robust, and comprehensive middleware platform for discovery data management and integration. The software platform provides the ability to perform complex, multi-stage queries across an unlimited data set, rapidly turning data into knowledge and increasing overall productivity.
Click here for more information about Scierra LWS discoveryHub
Amersham Biosciences, the life sciences business of Amersham (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences’ products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia. More information about Amersham Biosciences is available at www.amershambiosciences.com
Amersham Biosciences—enabling molecular medicine
geneticXchange provides the only open system data integration platform designed to accelerate new drug discovery. geneticXchange’s unique discoveryHub™ and discoveryBuilder™ software products enable rapid, real-time access, integration, normalization, and querying of all scientific data sources. The result is increased productivity, reduced risk and accelerated time-to-market for biotechnology and pharmaceutical companies. Leading organizations such as the Genome Institute of Singapore, Genomics Collaborative, and Signature BioScience leverage discoveryHub software to help realize the promise of in silico drug discovery. geneticXchange is headquartered in Menlo Park, CA, and can be reached at 650.321.9573, [email]info@geneticXchange.com[/email] or www.geneticxchange.com
Media Contact:
Helen Petts
Product PR Manager
T – +44 (0) 1494 498 068
helen.petts@amersham.com
